Tapan M. Kadia

32.7k citations

778 papers · 13.2k indexed · 3 hit papers · h-index 57

Hematology top 0.02%
- Acute Myeloid Leukemia Research 496
- Chronic Myeloid Leukemia Treatments 258
- Multiple Myeloma Research and Treatments 74
Genetics top 0.1%
- Chronic Lymphocytic Leukemia Research 218
- Myeloproliferative Neoplasms: Diagnosis and Treatment 148
Public Health, Environmental and Occupational Health top 0.2%
- Acute Lymphoblastic Leukemia research 201
Oncology top 1%
Molecular Biology top 1%
- Histone Deacetylase Inhibitors Research 107
- Protein Degradation and Inhibitors 72

Co-authors: Hagop M. Kantarjian Farhad Ravandi Guillermo Garcia‐Manero Elias Jabbour Jörge E. Cortes Gautam Borthakur Marina Konopleva Naval Daver
Cited by: Hematology Genetics Public Health, Environmental and Occupational Health
Journals: Journal of Clinical Oncology (89 papers)SHILAP Revista de lepidopterología (3 papers)Blood (358 papers)
Partner nations: United States Italy Japan

In The Last Decade

Tapan M. Kadia

713 papers receiving 13.1k citations

Hit Papers

align trajectories log scale

Peers

Countries citing papers authored by Tapan M. Kadia

Since Specialization

Citations

This map shows the geographic impact of Tapan M. Kadia's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tapan M. Kadia with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tapan M. Kadia more than expected).

Fields of papers citing papers by Tapan M. Kadia

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tapan M. Kadia. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tapan M. Kadia. The network helps show where Tapan M. Kadia may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Tapan M. Kadia, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Tapan M. Kadia Line = papers co-authored together Tapan M. Kadia links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Preclinical activity of investigational menin inhibitor DSP-5336 (Enzomenib)-based combinations against MLL1-rearranged (MLL-r) or mutant-NPM1 AML models Blood ·Warren Fiskus,Christopher P. Mill,Christine Birdwell,John A. Davis,Kaberi Das,Hanxi Hou,Surbhi Sharma,Steven L. Warner,Zhizhou Ye,Alicia K. Matthews,Kevin Philip,Tapan M. Kadia,Courtney D. DiNardo,Naval Daver,Kapil N. Bhalla	2025	0
2	Hyper-CVAD versus hyper-CVAD plus blinatumomab for adult patients with newly diagnosed Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis Blood ·Hannah Goulart,Hagop Kantarjian,Koji Sasaki,Nitin B. Jain,Caitlin R. Rausch,Tapan M. Kadia,Courtney D. DiNardo,Naval Daver,Naveen Pemmaraju,Farhad Ravandi,Guillermo Montalban‐Bravo,Guillermo Garcia‐Manero,Danielle Hammond,Mahesh Swaminathan,Rita Khouri,Maro Ohanian,Rebecca Garris,Nicholas J. Short,Elias Jabbour	2025	0
3	A Phase 2 study of CPX‐351 in combination with venetoclax in patients with newly diagnosed high‐risk acute myeloid leukemia HemaSphere ·Wei‐Ying Jen,Jennifer Croden,Emmanuel Almanza‐Huante,Courtney D. DiNardo,Kelly S. Chien,Danielle Hammond,Wei Qiao,Yesid Alvarado,Lucia Masárová,Andres Quesada,Sherry Pierce,Álex Bataller,Guillermo Garcia‐Manero,Amin Alousi,Nicholas J. Short,Naval Daver,Farhad Ravandi,Hagop Kantarjian,Tapan M. Kadia	2025	0
4	ASXL1 Mutations in AML Are Associated with a Distinct Epigenetic State Which Highlights Vulnerabilities to Specific Epigenetic-Targeted Agents Blood ·Christopher P. Mill,Warren Fiskus,Christine Birdwell,John A. Davis,Kaberi Das,Hanxi Hou,Surbhi Sharma,Koji Sasaki,Sanam Loghavi,Tapan M. Kadia,Naval Daver,Courtney D. DiNardo,Lu Wang,Kapil N. Bhalla	2024	1
5	Gemtuzumab Ozogamicin Added to Fludarabine, Cytarabine and G-CSF (FLAG-GO) Leads to Superior Molecular Response and Survival Outcomes Than Idarubicin (FLAG-IDA): 200 Patients Long-Term Follow up Blood ·Jayastu Senapati,H. Kantarjian,Edward Ayoub,Akhil Jain,Tapan M. Kadia,Courtney D. DiNardo,Naval Daver,Fadi Haddad,Naveen Pemmaraju,Nicholas J. Short,Maro Ohanian,Musa Yılmaz,Keyur P. Patel,Mark Brandt,Sherry Pierce,Guillermo Garcia‐Manero,Farhad Ravandi,Gautam Borthakur	2024	1
6	Phase Ib/II Study of CPX-351 Plus Venetoclax in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) Blood ·Vanthana Bharathi,Álex Bataller,Alexandre Bazinet,Gautam Borthakur,Elias Jabbour,Naval Daver,Nicholas J. Short,Koichi Takahashi,Ghayas C. Issa,Courtney D. DiNardo,Naveen Pemmaraju,Nitin Jain,Guillermo Montalban‐Bravo,William G. Wierda,Farhad Ravandi,H. Kantarjian,Tapan M. Kadia	2024	0
7	Cladribine-Based Therapy for Acute Myeloid Leukemia in Child, Adolescent, and Early Young Adult Patients: The MD Anderson Cancer Center Experience Cancers ·David McCall,Shaikha Alqahtani,Mustafa Budak,Irtiza Sheikh,Aaron E. Fan,Ramya Ramakrishnan,César Núnêz,Michael Roth,Miriam B. Garcia,Amber Gibson,Naval Daver,Sofía Garcés,Nicholas J. Short,Ghayas C. Issa,Farhad Ravandi,Courtney D. DiNardo,Guillermo Montalban‐Bravo,Guillermo Garcia‐Manero,Branko Cuglievan,Tapan M. Kadia	2024	1
8	Phase II Study of Cladribine with Low Dose Cytarabine and Venetoclax Alternating with Azacytidine and Venetoclax for Newly Diagnosed Acute Myeloid Leukemia Blood ·Álex Bataller,Hagop M. Kantarjian,Alexandre Bazinet,Jayastu Senapati,Gautam Borthakur,Nicholas J. Short,Elias Jabbour,Koichi Takahashi,Naval Daver,Ghayas C. Issa,Courtney D. DiNardo,Naveen Pemmaraju,Nitin Jain,Guillermo Montalban‐Bravo,Guillermo Garcia‐Manero,Farhad Ravandi,Tapan M. Kadia	2024	3
9	Outcomes of Patients With Treated Secondary Acute Myeloid Leukemia: A High‐Risk Subtype That Warrants an Independent Prognostic Designation American Journal of Hematology ·Jayastu Senapati,Hagop M. Kantarjian,Fadi Haddad,Nicholas J. Short,Gautam Borthakur,Rashmi Kanagal‐Shamanna,Guilin Tang,Elias Jabbour,Courtney D. DiNardo,Naval Daver,Guillermo Montalban‐Bravo,Vishrut Shah,Amin Alousi,Elizabeth Shpall,Uday Popat,Guillermo Garcia‐Manero,Farhad Ravandi,Tapan M. Kadia	2024	3
10	Efficacy and Safety of Gilteritinib versus Sorafenib as Post-Transplant Maintenance in Patients With FLT3-ITD Acute Myeloid Leukemia Clinical Lymphoma Myeloma & Leukemia ·Jason Yeh,Oren Pasvolsky,Rima M. Saliba,Bradley Figgins,Christopher Wang,Zhou Fang,Sairah Ahmed,Musa Yılmaz,Naval Daver,Farhad Ravandi,Courtney D. DiNardo,Nicholas J. Short,Tapan M. Kadia,Gheath Alatrash,May Daher,David Marin Costa,Uday Popat,Richard Champlin,Elizabeth J. Shpall,Betül Oran	2024	2
11	Cladribine, High-Dose AraC, Plus Gemtuzumab Ozogamicin (CLAG-GO) As Frontline Intensive Therapy for Fit Patients with Core-Binding Factor Acute Myeloid Leukemia: Preliminary Results Blood ·Georgina Gener‐Ricos,Gautam Borthakur,Koji Sasaki,Guilin Tang,Guillermo Montalban‐Bravo,Elias Jabbour,Maro Ohanian,Musa Yılmaz,Fadi Haddad,Kelly S. Chien,Jo Ishizawa,Nicholas J. Short,Abhishek Maiti,Mahesh Swaminathan,Guillermo Garcia‐Manero,Naval Daver,Courtney D. DiNardo,Farhad Ravandi,Tapan M. Kadia	2023	0
12	Clinical Characteristics and Contemporary Outcomes of Acute Myeloid Leukemia Evolving from Chronic Myelomonocytic Leukemia Blood ·Danielle Hammond,Tapan M. Kadia,Courtney D. DiNardo,Marina Konopleva,Nicholas J. Short,Naval Daver,Farhad Ravandi,Naveen Pemmaraju,Elias Jabbour,Kelly S. Chien,Sherry Pierce,Hagop M. Kantarjian,Guillermo Garcia‐Manero,Guillermo Montalban‐Bravo	2021	1
13	Outcomes of acute lymphoblastic leukemia with KMT2A (MLL) rearrangement: the MD Anderson experience Blood Advances ·Guillaume Richard‐Carpentier,Hagop M. Kantarjian,Guilin Tang,C. Cameron Yin,Joseph D. Khoury,Ghayas C. Issa,Fadi Haddad,Nitin Jain,Farhad Ravandi,Nicholas J. Short,Courtney D. DiNardo,Koichi Takahashi,Marina Konopleva,Naval Daver,Tapan M. Kadia,Guillermo Garcia‐Manero,Rebecca Garris,Susan O’Brien,Elias Jabbour	2021	25
14	Interim Analysis of a Phase II Study of the Glutaminase Inhibitor Telaglenastat (CB-839) in Combination with Azacitidine in Advanced Myelodysplastic Syndrome (MDS) Blood ·Veronica Guerra,Jan A. Burger,Gautam Borthakur,Elias Jabbour,Naveen Pemmaraju,Tapan M. Kadia,Guillermo Garcia‐Manero,Hagop M. Kantarjian,Marina Konopleva,Courtney D. DiNardo	2019	11
15	Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs Blood Advances ·Preetesh Jain,Hagop M. Kantarjian,Prajwal Boddu,Graciela M. Nogueras‐González,Srđan Verstovšek,Guillermo Garcia‐Manero,Gautam Borthakur,Koji Sasaki,Tapan M. Kadia,Princy Yohannan Sam,Hycienth Ahaneku,Susan O’Brien,Zeev Estrov,Farhad Ravandi,Elias Jabbour,Jörge E. Cortes	2019	85
16	Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia Blood ·Philipp B. Staber,Marco Herling,Mar Bellido,Eric Jacobsen,Matthew S. Davids,Tapan M. Kadia,Andrei R. Shustov,Olivier Tournilhac,Emmanuel Bachy,Francesco Zaja,Kimmo Porkka,Gregor Hoermann,Ingrid Simonitsch‐Klupp,Claudia Haferlach,Stefan Kubicek,Marius E. Mayerhoefer,Georg Hopfinger,Ulrich Jaeger,Claire Dearden	2019	67
17	Ponatinib and Bosutinib Discontinuation in Chronic Myeloid Leukemia (CML): Single Center Experience Blood ·Mansour Alfayez,Hagop M. Kantarjian,Tapan M. Kadia,Guillermo Garcia‐Manero,Farhad Ravandi,Gautam Borthakur,Courtney D. DiNardo,Mary Beth Rios,Elias Jabbour,Jörge E. Cortes	2018	1
18	P53 protein overexpression in de novo acute myeloid leukemia patients with normal diploid karyotype correlates with FLT3 internal tandem duplication and worse relapse‐free survival American Journal of Hematology ·Rita Assi,Hatice Gur,Sanam Loghavi,Sergej Konoplev,Marina Konopleva,Naval Daver,Mehrnoosh Tashakori,Tapan M. Kadia,Mark J. Routbort,Alireza Salem,Rashmi Kanagal‐Shamanna,Andres Quesada,Elias Jabbour,Steven M. Kornblau,L. Jeffrey Medeiros,Hagop M. Kantarjian,Joseph D. Khoury	2018	16
19	Response and Outcomes of Third-Line Tyrosine Kinase Inhibitor Therapy on Patients with Chronic Phase Chronic Myeloid Leukemia Blood ·Maliha Khan,Hagop M. Kantarjian,Jing Ning,Mary Akosile,Wen Li,Gautam Borthakur,Nitin Jain,Courtney D. DiNardo,William G. Wierda,Farhad Ravandi,Guillermo Garcia‐Manero,Marina Konopleva,Tapan M. Kadia,Naveen Pemmaraju,Philip A. Thompson,Naval Daver,Elias Jabbour,Jörge E. Cortes	2017	1
20	Preclinical and Early Clinical Evaluation of the Oral AKT Inhibitor, MK-2206, for the Treatment of Acute Myelogenous Leukemia Clinical Cancer Research ·Marina Konopleva,Roland B. Walter,Stefan Faderl,Elias Jabbour,Zhihong Zeng,Gautam Borthakur,Xuelin Huang,Tapan M. Kadia,Peter P. Ruvolo,Jennie B. Feliu,Hongbo Lu,LaKiesha Debose,Jan A. Burger,Michael Andreeff,Wenbin Liu,Keith Baggerly,Steven M. Kornblau,L. Austin Doyle,Elihu H. Estey,Hagop M. Kantarjian	2014	70

About Tapan M. Kadia

Tapan M. Kadia is a scholar working on Hematology, Genetics and Public Health, Environmental and Occupational Health, having authored 778 papers that have together received 13.2k indexed citations. Recurring topics across this work include Acute Myeloid Leukemia Research (496 papers), Chronic Myeloid Leukemia Treatments (258 papers), Chronic Lymphocytic Leukemia Research (218 papers), Acute Lymphoblastic Leukemia research (201 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (148 papers), Histone Deacetylase Inhibitors Research (107 papers), Multiple Myeloma Research and Treatments (74 papers) and Protein Degradation and Inhibitors (72 papers). The work is most often cited by research in Hematology (9.8k citations), Genetics (3.9k citations) and Public Health, Environmental and Occupational Health (3.0k citations). Tapan M. Kadia has collaborated with scholars based in United States, Italy and Japan. Frequent co-authors include Hagop M. Kantarjian, Farhad Ravandi, Guillermo Garcia‐Manero, Elias Jabbour, Jörge E. Cortes, Gautam Borthakur, Marina Konopleva, Naval Daver, Courtney D. DiNardo and Naveen Pemmaraju. Their work appears in journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact